Pan-Cancer Molecular Biomarkers
Clinics in Laboratory Medicine · 2024-06 · 44 (2) · 325-337
DOI: 10.1016/j.cll.2023.08.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics in Laboratory Medicine, 2024-06. Verfasst von Fei Dong. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, 3375 Hillview Ave, Palo Alto, CA 94304, USA. Electronic address: feidng@stanford.edu. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 92 Literaturangaben.
Abstract (Originalsprache)
The rapid adoption of next-generation sequencing in clinical oncology has enabled the detection of molecular biomarkers shared between multiple tumor types. These pan-cancer biomarkers include sequence-altering mutations, copy number changes, gene rearrangements, and mutational signatures and have been demonstrated to predict response to targeted therapy. This article reviews issues surrounding current and emerging pan-cancer molecular biomarkers in clinical oncology: technological advances that enable the broad detection of cancer mutations across hundreds of genes, the spectrum of driver and passenger mutations derived from human cancer genomes, and implications for patient care now and in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University School of Medicine, 3375 Hillview Ave, Palo Alto, CA 94304, USA. Electronic address: feidng@stanford.edu.
Zitieren
APA
Dong, F. (2024). Pan-Cancer Molecular Biomarkers. Clinics in Laboratory Medicine, 44(2), 325-337. https://doi.org/10.1016/j.cll.2023.08.013
Vancouver
Dong F. Pan-Cancer Molecular Biomarkers. Clinics in Laboratory Medicine. 2024;44(2):325-337. doi:10.1016/j.cll.2023.08.013
BibTeX
@article{Dong2024,
author = {Dong, Fei},
title = {Pan-Cancer Molecular Biomarkers},
journal = {Clinics in Laboratory Medicine},
year = {2024},
volume = {44},
number = {2},
pages = {325--337},
doi = {10.1016/j.cll.2023.08.013}
}
EUVIMED